AssetMark’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCRX
AssetMark's PCRX Position: Q3 2026 in Review
AssetMark increased its Pacira BioSciences (PCRX) stake by 16% in Q3 2026, buying an estimated $127 and bringing the position to 36 shares worth $902. The position accounts for ﹤0.01% of the portfolio, ranked #3256.
AssetMark first reported a position in PCRX in Q4 2017 and has held it in 6 quarters since. 205 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.
- AssetMark held 36 shares of Pacira BioSciences worth $902 as of Q3 2026.
- AssetMark bought 5 Pacira BioSciences shares in Q3 2026, an estimated $127.
- Pacira BioSciences made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3256 holding.
- AssetMark first reported a position in Pacira BioSciences in Q4 2017 and has held it in 6 quarters since.
- 205 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.